MARKET

AMLX

AMLX

Amylyx Pharmaceuticals
NASDAQ
29.86
-1.94
-6.10%
After Hours: 29.44 -0.42 -1.41% 19:57 11/12 EST
OPEN
31.43
PREV CLOSE
31.80
HIGH
31.57
LOW
29.79
VOLUME
1.47M
TURNOVER
--
52 WEEK HIGH
41.14
52 WEEK LOW
10.83
MARKET CAP
3.84B
P/E (TTM)
-20.6458
1D
5D
1M
3M
1Y
5Y
1D
Amylyx Pharmaceuticals Price Target Raised to $39.00/Share From $38.00 by Mizuho
Dow Jones · 2d ago
Amylyx Pharmaceuticals Is Maintained at Outperform by Mizuho
Dow Jones · 2d ago
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $39
Benzinga · 2d ago
Amylyx price target raised to $39 from $38 at Mizuho
TipRanks · 2d ago
Weekly Report: what happened at AMLX last week (1102-1106)?
Weekly Report · 3d ago
Amylyx Pharmaceuticals (AMLX) Stock Still Trades At A Premium As Phase 3 Progress Advances
Simply Wall St · 4d ago
Amylyx Stock Has The Bull Case Changed After Phase III Trial Success
Simply Wall St · 5d ago
Buy Rating Reaffirmed as Avexitide Data Support 2027 Launch Potential; $39 Price Target Unchanged
TipRanks · 6d ago
More
About AMLX
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on four investigational therapies across several diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome, AMX0114 in amyotrophic lateral sclerosis (ALS), and AMX0318 in PBH and other rare diseases. AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide and AMX0318 is a novel GLP-1 receptor antagonist.

Webull offers Amylyx Pharmaceuticals Inc stock information, including NASDAQ: AMLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMLX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMLX stock methods without spending real money on the virtual paper trading platform.